Using AI to predict and prevent low blood pressure during kidney treatment
AI driven acute renal replacement therapy - (AID-ART)
This study is looking at how smart computer technology can help doctors spot and prevent low blood pressure in critically ill patients receiving kidney treatment, so they can take action quickly and keep patients safer during their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10830320 on NIH RePORTER |
What this research studies
This research focuses on using advanced artificial intelligence techniques to predict and prevent intradialytic hypotension (IDH) in critically ill patients undergoing kidney replacement therapy. By analyzing high-frequency monitoring data and electronic health records, the study aims to identify patients at risk for low blood pressure during treatment, allowing for timely interventions. The goal is to improve patient outcomes by reducing complications associated with IDH, such as organ injury and increased mortality. The research will be conducted in intensive care units at the University of Pittsburgh Medical Center and the Mayo Clinic.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients with acute kidney injury who are receiving kidney replacement therapy in an intensive care setting.
Not a fit: Patients who are not critically ill or those who do not require kidney replacement therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the safety and effectiveness of kidney replacement therapy for critically ill patients.
How similar studies have performed: Previous research has shown promise in using predictive analytics for patient monitoring, indicating that this approach could lead to significant advancements in critical care management.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Murugan, Raghavan — University of Pittsburgh at Pittsburgh
- Study coordinator: Murugan, Raghavan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.